阿美特克 (AME) 2023 Q3 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good day, and welcome to the AMETEK Third Quarter 2023 Earnings Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded.

    各位早安,歡迎參加 AMETEK 2023 年第三季財報電話會議。(接線員指示)請注意,今天的會議將被錄音。

  • I would now like to hand the conference over to your speaker today, Kevin Coleman, Vice President of Investor Relations and Treasurer. Please go ahead.

    現在我想把會議交給今天的講者——投資人關係副總裁兼財務主管 Kevin Coleman。請開始。

  • Kevin C. Coleman - VP of IR & Treasurer

    Kevin C. Coleman - VP of IR & Treasurer

  • Thank you, Abigail. Good morning, and thank you for joining us for AMETEK's Third Quarter 2023 Earnings Conference Call. With me today are Dave Zapico, Chairman and Chief Executive Officer; and Bill Burke, Executive Vice President and Chief Financial Officer.

    謝謝你,Abigail。各位早安,感謝各位參加 AMETEK 2023 年第三季財報電話會議。今天與我一同出席的有董事長兼執行長 Dave Zapico,以及執行副總裁兼財務長 Bill Burke。

  • During the course of today's call, we will be making forward-looking statements, which are subject to change based on various risk factors and uncertainties that may cause actual results to differ significantly from expectations. A detailed discussion of the risks and uncertainties that may affect our future results is contained in AMETEK's filings with the SEC. AMETEK disclaims any intention or obligation to update or revise any forward-looking statements.

    在今天的電話會議過程中,我們將發表前瞻性陳述;此類陳述可能因各種風險因素與不確定性而有所變動,並可能導致實際結果與預期出現重大差異。關於可能影響我們未來業績之風險與不確定性的詳細討論,載於 AMETEK 向美國證券交易委員會(SEC)提交的文件中。AMETEK 不承擔更新或修訂任何前瞻性陳述的任何意圖或義務。

  • Any references made on this call to 2022 or 2023 results or to 2023 guidance will be on an adjusted basis, excluding after tax, acquisition-related intangible amortization. Reconciliations between GAAP and adjusted measures can be found in our press release and on the Investors section of our website.

    本次電話會議中任何提及 2022 或 2023 年業績,或 2023 年指引者,均以調整後基礎呈現,並排除稅後之併購相關無形資產攤銷。GAAP 與調整後衡量指標之間的調節表可見於我們的新聞稿以及官網「投資人」專區。

  • We'll begin today's call with prepared remarks by Dave and Bill, and then we'll open it up for questions. I'll now turn the meeting over to Dave.

    今天的會議將先由 Dave 與 Bill 發表準備好的談話,接著開放提問。現在我把會議交給 Dave。

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Thank you, Kevin, and good morning, everyone. AMETEK delivered excellent results in the third quarter, highlighted by outstanding operational execution, superb margin expansion, strong cash flows and earnings ahead of our expectations. In the quarter, we established records for operating income, operating margins, earnings per share, EBITDA and cash flows. Given these strong results and our outlook for the balance of the year, we have, again, increased our earnings guidance for the full year.

    謝謝你,Kevin,各位早安。AMETEK 在第三季交出極佳成績,亮點包括卓越的營運執行、出色的毛利率/利潤率擴張、強勁的現金流,以及優於我們預期的獲利。本季我們在營業利益、營業利益率、每股盈餘、EBITDA 與現金流方面皆創下紀錄。鑑於這些強勁成果以及我們對今年剩餘期間的展望,我們再次上調全年獲利指引。

  • We have also been very active on the acquisition front. During the third quarter, we completed the acquisition of United Electronic Industries and subsequent to the end of the third quarter, we acquired Amplifier Research. Today, we also announced the signing of a definitive purchase agreement to acquire Paragon Medical, a highly attractive acquisition, which broadens our exposure in the medical technology space. I will provide more details on these acquisitions shortly.

    我們在併購方面也非常積極。第三季期間,我們完成對 United Electronic Industries 的收購;並在第三季結束後收購了 Amplifier Research。今天我們也宣布已簽署最終購買協議,將收購 Paragon Medical——這是一項極具吸引力的併購案,可擴大我們在醫療科技領域的布局。我稍後將提供更多關於這些併購的細節。

  • Now let me turn to our third quarter results. Third quarter sales were $1.62 billion, up 5% over the same period in 2022. Organic sales growth was flat. Acquisitions added 4 points in the quarter and foreign currency added 1 point. Book-to-bill in the quarter was 0.96. We ended the quarter with a very strong backlog of $3.4 billion, near record levels and down a modest 2% sequentially. Our backlog is up 5% from last year's third quarter and up 23% or $640 million from the end of 2021.

    接著說明第三季業績。第三季銷售額為 16.2 億美元,較 2022 年同期成長 5%。有機銷售成長持平。併購在本季貢獻 4 個百分點,外匯貢獻 1 個百分點。本季接單出貨比(book-to-bill)為 0.96。我們在季末的在手訂單(backlog)達 34 億美元,接近歷史高點,較前一季小幅下降 2%。在手訂單較去年第三季成長 5%,較 2021 年底增加 23%(或 6.4 億美元)。

  • AMETEK's operating performance in the third quarter was exceptional. Operating income in the quarter was a record $438 million, a 14% increase over the third quarter of 2022. Operating margins were a record 27% in the quarter, up a sizable 220 basis points from the prior year. EBITDA in the quarter was also a record at $511 million, up 10% over the prior year, with EBITDA margin, an impressive 31.5%.

    AMETEK 第三季的營運表現非常出色。本季營業利益創紀錄達 4.38 億美元,較 2022 年第三季成長 14%。本季營業利益率創紀錄達 27%,較去年同期大幅提升 220 個基點。本季 EBITDA 亦創紀錄達 5.11 億美元,較去年同期成長 10%,EBITDA 利潤率達到令人印象深刻的 31.5%。

  • Operating cash flow was up 45% in the quarter to a record $473 million. This outstanding performance led to record earnings of $1.64 per diluted share, up 13% versus the third quarter of 2022 and above our guidance range of $1.56 to $1.58.

    本季營運現金流年增 45%,創紀錄達 4.73 億美元。這項傑出表現帶動稀釋後每股盈餘創紀錄達 1.64 美元,較 2022 年第三季成長 13%,並高於我們 1.56 至 1.58 美元的指引區間。

  • Now let me provide some additional details at the operating group level. First, the Electronic Instruments Group. The Electronic Instruments Group delivered impressive operating performance, with continued strong and broad-based sales growth. Sales for EIG were $1.14 billion in the quarter, up 8% from the third quarter of last year. Organic sales were up 3.5%, acquisitions added 3.5% and foreign currency added a point. EIG's organic sales growth remains broad-based and reflects our leading position across attractive market segments and the impact of our organic growth initiatives.

    接著我將在營運事業群層級提供更多細節。首先是電子儀器事業群(Electronic Instruments Group,EIG)。EIG 繳出亮眼的營運表現,銷售成長持續強勁且涵蓋面廣。本季 EIG 銷售額為 11.4 億美元,較去年第三季成長 8%。有機銷售成長 3.5%,併購貢獻 3.5%,外匯貢獻 1 個百分點。EIG 的有機成長仍相當廣泛,反映我們在具吸引力的市場區隔中具領先地位,以及我們有機成長計畫所帶來的成效。

  • Growth in the quarter was particularly strong across our Aerospace & Defense businesses as well as in our Zygo, SPECTRO and CAMECA businesses. Third quarter operating income was a record $335 million, up 23% versus the prior year. And operating margins were a record 29.5% in the quarter, up an impressive 360 basis points from the prior year, tremendous work by our EIG businesses in the third quarter.

    本季成長在航太與國防相關業務,以及 Zygo、SPECTRO 與 CAMECA 業務方面尤為強勁。第三季營業利益創紀錄達 3.35 億美元,較去年同期成長 23%。本季營業利益率亦創紀錄達 29.5%,較去年同期大幅提升 360 個基點;EIG 各事業在第三季的表現非常出色。

  • The Electromechanical Group also delivered solid operating performance in the quarter, despite the impact of normalization of inventory levels across our OEM customer base. EMG's third quarter sales were $487 million, down 2% versus the prior year, with organic sales down 8% in the quarter. Acquisitions added 4 points and foreign currency added 2 points. EMG's operating income in the quarter was $128 million, down 7% compared to the prior year period, while EMG's third quarter operating margins were a very solid 26.2%.

    機電事業群(Electromechanical Group,EMG)在本季也繳出穩健的營運表現,儘管我們 OEM 客戶群的庫存水位正常化帶來影響。EMG 第三季銷售額為 4.87 億美元,較去年同期下降 2%,本季有機銷售下降 8%。併購貢獻 4 個百分點,外匯貢獻 2 個百分點。EMG 本季營業利益為 1.28 億美元,較去年同期下降 7%;而 EMG 第三季營業利益率仍維持在相當穩健的 26.2%。

  • Our performance in the third quarter, and thus far in 2023, reflects the unique value inherent in the AMETEK growth model. Our differentiated businesses are aligned with diverse and attractive growth markets, while our organic growth initiatives continue to position us for long-term sustainable growth.

    我們在第三季以及 2023 年迄今的表現,反映 AMETEK 成長模式所內含的獨特價值。我們具差異化的事業與多元且具吸引力的成長市場相契合,同時我們的有機成長計畫也持續讓我們具備長期、可持續的成長動能。

  • Our distributed operating structure provides our businesses with the ability to execute their growth strategy and the flexibility to react quickly to changing market conditions. And our asset-light business model and strong operational execution drive outstanding cash flow generation, which we redeploy on value-enhancing acquisitions. This strong cash flow and our robust balance sheet are key differentiators for AMETEK in this higher interest rate environment.

    我們分散式的營運架構,使各事業能夠執行其成長策略,並具備快速因應市場變化的彈性。同時,我們的輕資產商業模式與強勁的營運執行,帶來卓越的現金流創造能力,並將其再投入於提升價值的併購。在利率較高的環境下,這樣的強勁現金流與穩健資產負債表,是 AMETEK 的關鍵差異化優勢。

  • Now switching to our acquisition strategy. As noted, we have been very active in managing a strong pipeline of acquisition opportunities. We are pleased to welcome our most recent acquisitions, United Electronic Industries and Amplifier Research. I'm pleased that we have signed a definitive agreement to acquire Paragon Medical. I will provide some more color on each of these businesses, starting with Paragon Medical.

    接著談我們的併購策略。如前所述,我們一直積極管理強勁的併購機會管線。我們很高興歡迎最新完成的併購案:United Electronic Industries 與 Amplifier Research。我也很高興我們已簽署最終協議收購 Paragon Medical。以下我將就這三家公司提供更多說明,先從 Paragon Medical 開始。

  • Paragon Medical is a leading manufacturer of highly engineered medical components and instruments serving applications, including orthopedics, minimally invasive surgery, robotic surgery and drug delivery solutions. Paragon's broad product portfolio of single-use and implantable components are sold to a diverse blue-chip customer base of leading medical device OEMs.

    Paragon Medical 是高度工程化醫療零組件與器械的領先製造商,服務的應用包括骨科、微創手術、機器人手術以及藥物輸送解決方案。Paragon 擁有廣泛的產品組合,涵蓋一次性使用與可植入式零組件,銷售給多元的優質客戶群,包括多家領先的醫療器材 OEM。

  • Paragon is an excellent acquisition for AMETEK. It expands our presence in the med tech space and provides us with access to attractive new market segments with strong growth rates. We are acquiring Paragon in an all-cash transaction valued at approximately $1.9 billion. Paragon has annual sales of approximately $500 million and is headquartered in Pierceton, Indiana. The closing of the acquisition is subject to customary closing conditions, including applicable regulatory approvals.

    Paragon 對 AMETEK 而言是一項極佳的併購案。它將擴大我們在醫療科技領域的布局,並讓我們進入具高成長率、極具吸引力的新市場區隔。我們將以全現金交易收購 Paragon,交易價值約 19 億美元。Paragon 年營收約 5 億美元,總部位於印第安納州 Pierceton。本次收購案的完成仍須符合慣常交割條件,包括取得適用的監管核准。

  • Now switching to United Electronic Industries, or UEI, which we acquired in August. UEI is a leading provider of ruggedized test, measurement, simulation and control solutions. UEI's custom products cater to diverse data acquisition needs from hardware in the loop testing, to aircraft simulators and automated testing systems and mission-critical applications.

    接著談 United Electronic Industries(UEI),我們已於 8 月完成收購。UEI 是耐用型(ruggedized)測試、量測、模擬與控制解決方案的領先供應商。UEI 的客製化產品可滿足多元的資料擷取需求,涵蓋硬體迴路(hardware-in-the-loop)測試、飛行模擬器與自動化測試系統,以及任務關鍵型應用。

  • With a strong presence in the defense, aerospace nuclear power generation and semiconductor, UEI nicely complements AMETEK's Power Systems and Instruments division, significantly expanding our data acquisition capabilities. UEI has annual sales of approximately $35 million and is based in Norwood, Massachusetts.

    UEI 在國防、航太、核能發電與半導體領域具備強勁布局,與 AMETEK 的電力系統與儀器事業部形成良好互補,並大幅擴充我們的資料擷取能力。UEI 年營收約 3,500 萬美元,據點位於麻薩諸塞州 Norwood。

  • Next, Amplifier Research is a leading provider of innovative RF and microwave solutions. Its equipment is used for electromagnetic compatibility testing within the defense, industrial, automotive, medical and communication sectors. Amplifier Research is an outstanding strategic acquisition and complementary fit with our existing compliance test solutions business. Their technical capability has broaden our RF instrumentation and testing portfolio.

    接下來,Amplifier Research 是創新 RF 與微波解決方案的領先供應商。其設備用於國防、工業、汽車、醫療與通訊等領域的電磁相容性(EMC)測試。Amplifier Research 是一項卓越的策略性併購,並與我們既有的合規測試解決方案業務高度互補。他們的技術能力擴大了我們的 RF 儀器與測試產品組合。

  • Amplifier Research is a growing business, well positioned to benefit from the growth in demand for electric vehicle research, development and testing. Amplifier Research is based in Souderton, PA, and has annual sales of approximately $60 million. Our acquisition pipeline remains very solid. We have a strong balance sheet and significant financial capacity and look to remain active in deploying capital in the coming quarters. AMETEK also remains committed to investing in our businesses to help position them for long-term sustainable organic growth. In 2023, we plan to invest approximately $100 million in these growth initiatives, including our new product development efforts where our businesses continue to develop highly differentiated technologies to help solve our customers' most complex challenges.

    Amplifier Research 是一家成長中的企業,具備良好定位,可受惠於電動車研發與測試需求的成長。Amplifier Research 位於賓夕法尼亞州 Souderton,年營收約 6,000 萬美元。我們的併購管線仍然非常穩健。我們擁有強健的資產負債表與顯著的財務能力,並期望在未來幾季持續積極部署資本。AMETEK 也將持續投入資源於各項事業,以協助其建立長期、可持續的有機成長動能。2023 年我們計畫在這些成長計畫上投資約 1 億美元,其中包括新產品開發工作;我們的事業持續開發高度差異化的技術,以協助解決客戶最複雜的挑戰。

  • In the quarter, our Vitality Index, which measures sales from products introduced over the prior 3 years, were a healthy 26%. As a complement to our internal new product development efforts, our ORTEC business recently acquired a small technology company, innoRIID, to help broaden their technology capabilities in the radiation detection market.

    在本季度,我們的活力指數(Vitality Index,用以衡量過去3年內推出產品所帶來的銷售)維持在健康的26%。作為我們內部新產品開發工作的補充,我們的 ORTEC 業務近期收購了一家小型科技公司 innoRIID,以協助擴展其在輻射偵測市場的技術能力。

  • innoRIID, both cutting-edge technology expertise and an exceptional product development team known for their innovative solutions, having developed specialized artificial intelligence algorithms for radiation detection in a range of nuclear security, research, health and medical applications.

    innoRIID 具備尖端技術專長以及以創新解決方案聞名的卓越產品開發團隊,並已針對核安、防護研究、健康與醫療等多元應用領域的輻射偵測,開發出專門的人工智慧演算法。

  • Now turning to our outlook for the remainder of the year. With strong performance in the third quarter and a positive outlook for the remainder of the year, we are, once again, raising our earnings guidance. For the full year, we continue to expect overall sales to be up mid- to high single digits, and we continue to expect organic sales to be up mid-single digits.

    接著談談我們對今年剩餘期間的展望。第三季表現強勁,且對今年其餘時間的前景正向,因此我們再次上調獲利指引。就全年而言,我們仍預期整體銷售將成長中至高個位數百分比,並且仍預期有機銷售將成長中個位數百分比。

  • Diluted earnings per share for the year are now expected to be in the range of $6.31 to $6.33, up approximately 11% compared to last year's results. This is an increase from our previous guidance range of $6.18 to $6.26 per diluted share. For the fourth quarter, we anticipate overall sales to be up mid-single digits, with adjusted earnings of $1.61 to $1.63 per share, up 6% to 7% versus the prior year.

    今年稀釋後每股盈餘目前預期落在 6.31 至 6.33 美元區間,較去年結果約成長 11%。這較我們先前每股稀釋後 6.18 至 6.26 美元的指引區間有所上調。就第四季而言,我們預期整體銷售將成長中個位數百分比,調整後每股盈餘為 1.61 至 1.63 美元,較去年同期成長 6% 至 7%。

  • In summary, AMETEK's third quarter results for 2023 were outstanding, with strong growth across our long-cycle businesses, record operating performance and strong acquisition activity. Our businesses continue to excel, driven by our differentiated technology solutions serving diverse and growing markets. Our asset-light business model and strong cash flows provide us with the flexibility to navigate challenging economic environments, while actively deploying capital to enhance shareholder value. AMETEK remains firmly positioned for long-term sustainable growth.

    總結而言,AMETEK 2023 年第三季的業績表現卓越,長週期業務全面強勁成長、營運表現創新高,且併購活動活躍。我們的各項業務持續表現出色,動能來自我們具差異化的技術解決方案,服務於多元且成長中的市場。我們的輕資產商業模式與強勁現金流,讓我們在具挑戰的經濟環境中仍具備靈活性,同時積極部署資本以提升股東價值。AMETEK 仍穩固地站在長期可持續成長的位置上。

  • I will now turn it over to Bill Burke, who will cover some of the financial details of the quarter. Then we'll be glad to take your questions. Bill?

    接下來我把時間交給 Bill Burke,他將說明本季的一些財務細節。之後我們很樂意回答各位的問題。Bill?

  • William Joseph Burke - Executive VP & CFO

    William Joseph Burke - Executive VP & CFO

  • Thank you, Dave. As Dave noted, AMETEK delivered outstanding results in the third quarter, with exceptional operating performance, robust margin expansion and strong cash flows. Let me provide some additional financial highlights for the quarter.

    謝謝你,Dave。正如 Dave 所提到的,AMETEK 在第三季交出亮眼成績,營運表現卓越、利潤率大幅擴張且現金流強勁。讓我補充本季的一些財務重點。

  • Third quarter general and administrative expenses were $24.6 million, essentially unchanged from the prior year, and as a percentage of sales, were 1.5% versus 1.6% in last year's third quarter. For 2023, general administrative expenses are expected to be approximately 1.5% of sales, in line with last year's G&A to sales level. Other income and expense was a headwind of $9 million in the quarter, due largely to lower pension income and higher due diligence costs. The effective tax rate in the quarter was 17.7%, down from 19% in the third quarter of 2022, due to improved utilization of tax credits. For 2023, we now anticipate our effective tax rate to be between 18.5% and 19%. And as we stated in the past, actual quarterly tax rates can differ dramatically, either positively or negatively from this full year estimated rate.

    第三季一般及管理費用為 2,460 萬美元,與去年同期基本持平;以銷售額百分比計為 1.5%,去年第三季為 1.6%。2023 年全年,一般及管理費用預期約占銷售額的 1.5%,與去年 G&A 占比水準一致。本季其他收益與費用為 900 萬美元的不利因素,主要由於退休金收益較低以及盡職調查成本較高。本季有效稅率為 17.7%,低於 2022 年第三季的 19%,原因是稅額抵減的使用效率提升。2023 年全年,我們目前預期有效稅率介於 18.5% 至 19%。如同過去所述,實際季度稅率可能相較於全年估計稅率出現顯著差異,可能偏正面也可能偏負面。

  • Capital expenditures in the third quarter were $29 million, and we continue to expect capital expenditures to be approximately $145 million for the full year or about 2% of sales. Depreciation and amortization expense in the quarter was $82 million. For the full year, we expect depreciation and amortization to be approximately $330 million, including after-tax, acquisition-related intangible amortization of approximately $157 million or $0.68 per share.

    第三季資本支出為 2,900 萬美元;我們仍預期全年資本支出約為 1.45 億美元,約占銷售額的 2%。本季折舊與攤銷費用為 8,200 萬美元。就全年而言,我們預期折舊與攤銷約為 3.30 億美元,其中包含稅後、與併購相關的無形資產攤銷約 1.57 億美元,或每股 0.68 美元。

  • Operating working capital in the third quarter was 19.1% of sales. Cash flow was excellent in the quarter with outstanding growth versus the prior year. Operating cash flow was a record $473 million, up 45% versus the third quarter of 2022, while free cash flow was also a record at $444 million, up 49% over the prior year. Free cash flow conversion was 131% in the quarter. And for the full year, we continue to expect approximately 120% free cash flow to net income conversion.

    第三季營運週轉資金占銷售額的 19.1%。本季現金流表現極佳,較去年同期大幅成長。營運現金流創紀錄達 4.73 億美元,較 2022 年第三季成長 45%;自由現金流亦創紀錄達 4.44 億美元,較去年同期成長 49%。本季自由現金流轉換率為 131%。就全年而言,我們仍預期自由現金流對淨利的轉換率約為 120%。

  • Total debt at September 30 was $2.2 billion, down from $2.4 billion at the end of 2022. Offsetting this debt is cash and cash equivalents of $842 million. At the end of the third quarter, our gross debt-to-EBITDA ratio was 1.1x, and our net debt-to-EBITDA ratio was 0.6x, leaving us with significant available cash and financial capacity to deploy on strategic acquisitions. As Dave has noted, we've been very active.

    截至 9 月 30 日,總負債為 22 億美元,低於 2022 年底的 24 億美元。與此負債相抵的是 8.42 億美元的現金及約當現金。第三季末,我們的總負債對 EBITDA 比率為 1.1 倍,淨負債對 EBITDA 比率為 0.6 倍,使我們仍擁有充足可用現金與財務能力,可用於策略性併購部署。正如 Dave 所提到的,我們一直非常積極。

  • During the third quarter, we deployed approximately $150 million on the acquisitions of UEI and innoRIID. And subsequent to the end of the quarter, we deployed approximately $105 million on the acquisition of Amplifier Research. Also subsequent to the end of the third quarter, we announced the signing of a definitive agreement to acquire Paragon Medical for $1.9 billion, which would be our largest acquisition to date. Following the acquisition of Paragon, we would still have significant financial capacity with approximately $1.5 billion of cash in existing credit facilities available to support our growth initiatives.

    第三季期間,我們在收購 UEI 與 innoRIID 上部署了約 1.50 億美元。且在季末之後,我們在收購 Amplifier Research 上部署了約 1.05 億美元。同樣在第三季結束後,我們宣布已簽署最終協議,以 19 億美元收購 Paragon Medical,這將是我們迄今最大的一筆收購。完成 Paragon 收購後,我們仍將保有可觀的財務能力,現有授信額度中約有 15 億美元的可用現金可支援我們的成長計畫。

  • In summary, AMETEK had exceptional results in the third quarter. We achieved significant margin expansion and delivered high-quality earnings. Our strong position in key market segments, coupled with a very strong backlog and exceptional operating capabilities, positions us well for continued success. Kevin?

    總結而言,AMETEK 第三季表現極為出色。我們實現顯著的利潤率擴張,並交出高品質的獲利。我們在關鍵市場區隔的強勢地位,加上非常強勁的在手訂單與卓越的營運能力,使我們具備持續成功的良好條件。Kevin?

  • Kevin C. Coleman - VP of IR & Treasurer

    Kevin C. Coleman - VP of IR & Treasurer

  • Thank you, Bill. Abigail, could we please open the lines for questions?

    謝謝你,Bill。Abigail,能否請你開放電話線讓大家提問?

  • Operator

    Operator

  • (Operator Instructions) Our first question comes from Deane Dray with RBC Capital Markets.

    (接線員指示)我們的第一個問題來自 RBC Capital Markets 的 Deane Dray。

  • Deane Michael Dray - MD of Multi-Industry & Electrical Equipment & Analyst

    Deane Michael Dray - MD of Multi-Industry & Electrical Equipment & Analyst

  • Congrats on all the M&A successes here. Maybe we can start with Paragon. It looks right in your wheelhouse, Precision Medical, robotics. If you could provide some color on the company in terms of like what percent are consumables? We're really like seeing all those one use applications. So consumables, comment on margins and growth, if you could, please?

    恭喜你們在併購方面的多項成功。或許我們可以先從 Paragon 開始。看起來它非常符合你們的核心能力:精密醫療、機器人。如果可以的話,能否多分享一些關於這家公司組成的細節,例如耗材占比是多少?我們確實看到許多一次性使用的應用在增加。所以想請你們談談耗材占比、利潤率與成長性,謝謝。

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Yes. Sure. I'll give you my view of Paragon. As you stated, the leading provider of highly engineered medical components and instruments. When you look at the key market drivers of this acquisition, you have the aging population, the demographic shifts. You also have procedure innovation, where the minimally invasive procedures are becoming more percentages of surgeries, and they do a great job with that.

    好的,當然。我來談談我對 Paragon 的看法。如你所說,它是高度工程化醫療零組件與器械的領先供應商。從這筆收購的主要市場驅動因素來看,包括人口老化與人口結構變化;也包括手術方式的創新,微創手術在各類手術中的占比持續提高,而他們在這方面做得非常出色。

  • And also in this market, there's a continuing trend toward outsourcing the OEMs. And they want to -- the OEMs want to accelerate their time to market, and Paragon is really well positioned with significant new product wins in this space. It serves specialty applications. I talked about the orthopedics, minimally invasive surgery, robotic surgery and drug delivery.

    此外,在這個市場中,OEM 持續朝外包趨勢發展。OEM 希望加速產品上市時程,而 Paragon 在此領域具備良好定位,並在這個領域取得大量新產品專案的勝出。其服務涵蓋專業應用。我提到的包括骨科、微創手術、機器人手術以及藥物輸送。

  • Orthopedics is the largest, but they're strong positions in each of the applications. Now the portfolio is one of your questions, consisted of single-use and consumable surgical instruments and implantable components, and about 40% of the business is recurring in nature. So the single-use and consumables surgical instruments are about 40% of the revenue. So we really like that.

    骨科是最大的一塊,但他們在各項應用中都具備強勢地位。至於你問到的產品組合,包含一次性使用與耗材型手術器械,以及可植入式零組件;其中約 40% 的業務屬於經常性收入性質。因此,一次性與耗材型手術器械約占營收的 40%。我們非常喜歡這一點。

  • As a blue chip customer base, over 600 programs, with diverse sources of revenue. About 85% of the business is on sole-source programs. It's a very, very sticky business. When you combine the regulatory environment with lengthy approval processes and the capabilities of Paragon, there's high switching costs.

    其客戶基礎屬於一流等級(blue chip),擁有超過 600 個專案,收入來源多元。約 85% 的業務來自單一來源(sole-source)專案。這是一門非常、非常黏著度高的生意。結合監管環境、冗長的核准流程以及 Paragon 的能力,轉換成本很高。

  • It's a business that has unique value to its customer base. We did a lot of surveys in the market, and they're the highest quality provider. They have excellent customer service. A differentiator for them is their design and development capability. And I really considered a true partner by their customers.

    這是一項對其客戶群具有獨特價值的業務。我們在市場上做了大量調查,他們是品質最高的供應商;客戶服務也非常出色。他們的一項差異化優勢在於設計與開發能力。我也認為他們被客戶視為真正的合作夥伴。

  • And when I look at this from -- that's about Paragon. When I look at what it does for AMETEK, it increases our med tech exposure now to over 20%. It's one of the goals we've been trying to achieve. It adds about $500 million of revenue to EMG, and that revenue is -- comes from Paragon, which is a secular low double-digit grower.

    從 Paragon 本身大致如此。再來看它對 AMETEK 的意義:它將我們在醫療科技(med tech)的曝險提高到超過 20%,這是我們一直努力達成的目標之一。它為 EMG 增加約 5 億美元的營收,而這些營收來自 Paragon;Paragon 在結構性趨勢帶動下,屬於低雙位數成長的公司。

  • It really fits our business model with the highly engineered products that provide unique value to customers. It's a growing, profitable business that provides multiple avenues of growth. And there's really an opportunity for us to improve margins by applying the AMETEK growth model. It's already a profitable business, but there's plenty of room for us to apply the AMETEK growth model and expand margins.

    這確實非常符合我們的商業模式:以高度工程化的產品為客戶提供獨特價值。這是一項正在成長且具獲利能力的業務,並提供多條成長途徑。而且,透過套用 AMETEK 成長模式,我們確實有機會提升利潤率。它本身已是獲利的業務,但仍有很大的空間讓我們運用 AMETEK 成長模式並擴大利潤率。

  • Paragon will benefit from the AMETEK's global infrastructure for sure, and we like the management team. They're a highly talented team, and we're excited about what we can accomplish together. And importantly, the deal economics meant AMETEK's traditional [dealers], and this is on a large deployment of capital. So our return on invested capital orders are met by this deal.

    Paragon 肯定會受益於 AMETEK 的全球基礎設施,而我們也很喜歡他們的管理團隊。他們是一支非常有才華的團隊,我們對於能一起完成的事情感到興奮。更重要的是,這筆交易的經濟性符合 AMETEK 一貫的[交易準則],而且這是一筆大規模的資本部署。因此,這筆交易能滿足我們對投入資本報酬率的要求。

  • And we paid about 15x TTM EBITDA for the business. So we're very excited for the business. It's a good business for us. We've been looking at these businesses for some time and it's a universal excitement amongst Paragon and AMETEK.

    我們為這項業務支付了約 15 倍的過去十二個月(TTM)EBITDA。因此我們對這項業務非常興奮。這對我們而言是一門好生意。我們已經關注這類業務一段時間了,Paragon 與 AMETEK 對此都有一致的期待與興奮。

  • Deane Michael Dray - MD of Multi-Industry & Electrical Equipment & Analyst

    Deane Michael Dray - MD of Multi-Industry & Electrical Equipment & Analyst

  • All right. That was a great overview, and you hit all the key questions on the consumables, margins and growth. So it sounds like a great story. And if I could just -- on a follow-up question on EMG. So we're seeing destocking all over the sector in biopharma and med tech.

    好的。這是很棒的概述,你也涵蓋了耗材、利潤率與成長等所有關鍵問題。聽起來是一個很好的故事。我想追問一下 EMG。現在我們在生物製藥與醫療科技領域都看到整個產業在去庫存。

  • Be interested in hearing from you, besides the destocking, is there any kind of read-through on the end markets in those businesses? Are you seeing any slowing there? And look, no one's getting -- no one has a crystal ball here in terms of how long you think this lasts, but I'd love to hear your expectation on the duration of this inventory normalization.

    我想聽聽你們的看法:除了去庫存之外,這些業務的終端市場是否有任何可供推論的訊號?你們有看到那邊放緩嗎?另外,當然沒有人能——沒有人有水晶球能判斷這會持續多久,但我很想聽聽你對這波庫存正常化持續時間的預期。

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Yes. Sure, Deane. Great questions. For the quarter, we grew our top line 5% on a mid-single-digit guide. Our revenue was in line with the guides. The acquisition performed a bit better. And we maintained, as I said, our full year sales guide mid- to high single digits and organic growth of mid-single digits. To maintain that organic guide for the full year, our Aerospace & Defense business is stronger and our automation is weaker. And they're offsetting. That's one of the benefits of the AMETEK portfolio. And specifically in terms of Q3 revenue, we saw faster destocking in our automation businesses than we anticipated. So that's what we saw there. And we expect the destocking to continue through the end of the year.

    是的,當然,Deane。很好的問題。本季我們在中個位數成長指引下,營收成長 5%。我們的營收符合指引。併購案的表現稍微更好一些。而且如我所說,我們維持全年銷售指引在中到高個位數,以及有機成長中個位數。為了維持全年有機成長指引,我們的航太與國防業務較強,而自動化較弱,兩者互相抵銷。這就是 AMETEK 投資組合的好處之一。特別就第三季營收而言,我們在自動化業務看到的去庫存速度比我們預期更快。因此我們看到的是這個情況。我們預期去庫存將持續到年底。

  • In terms of your question, is it a destock or a downturn? It's very difficult dynamic environment right now and lots of uncertainties, with the geopolitical risk, the interest rate increases. They're factoring in, for sure. But from what we see, this is largely an inventory correction. And demand looks constructive, with many new projects in the offing and the projects are not being delayed or canceled.

    至於你的問題:這是去庫存還是景氣下行?目前環境非常動態且充滿不確定性,地緣政治風險、利率上升等因素確實都在影響。但就我們所見,這主要是庫存修正。需求看起來仍具建設性,許多新專案正在醞釀中,而且專案並沒有延後或取消。

  • Our aerospace and defense looks solid. Our medical looks sold. Significant projects and semiconductor, clean energy, power grid. So we remain positive post destocking. And we think that destocking will continue through the end of the year. And in terms of 2024, we're going to sit down with our teams and understand what's going on. But in general, we're constructive.

    我們的航太與國防看起來穩健;醫療看起來也很穩。半導體、潔淨能源、電網等都有重要專案。因此在去庫存之後我們仍保持正向。我們認為去庫存會持續到年底。至於 2024 年,我們會和團隊坐下來了解狀況;但整體而言,我們仍偏向正面看待。

  • Operator

    Operator

  • Our next question comes from Matt Summerville with D.A. Davidson.

    下一個問題來自 D.A. Davidson 的 Matt Summerville。

  • Matt J. Summerville - MD & Senior Research Analyst

    Matt J. Summerville - MD & Senior Research Analyst

  • Dave, your EIG margin this quarter really moved into a new zip code for AMETEK. I was wondering if you could maybe talk about the key drivers as you just think about the sequential performance, right, Rev flat profitability up $28 million on the OP line as well as kind of the year-over-year dynamics. So maybe if you can just kind of flesh all of that out, that would be helpful. And then I have a follow-up.

    Dave,你們本季 EIG 的利潤率真的提升到 AMETEK 的新高度。我想請你談談關鍵驅動因素,尤其是你如何看待環比表現:營收持平,但在營業利益(OP)線上獲利增加了 2,800 萬美元,以及同比的動態。若你能把這些再具體說明一下會很有幫助。然後我還有一個追問。

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Yes, sure, Matt. I mean if you'll go back and look at my last quarter or 2, I told you, EIG was gaining momentum, and the momentum certainly showed up in Q3. We had an excellent operating quarter. I mean EIG margins were up 360 basis points, driven by high contribution leverage on the growth. We really had excellent price cost. We had strongly performing acquisitions, and it all came together to put up record margins.

    好的,當然,Matt。如果你回去看我過去一兩季的說法,我提到 EIG 正在累積動能,而這個動能在第三季確實展現出來。我們有一個非常出色的營運季度。EIG 利潤率提升了 360 個基點,主要由成長帶來的高貢獻度槓桿所驅動。我們的價格與成本表現非常好;併購案表現也很強勁,所有因素匯聚在一起,推動利潤率創下新高。

  • Matt J. Summerville - MD & Senior Research Analyst

    Matt J. Summerville - MD & Senior Research Analyst

  • And then just as a follow-up. With respect to Paragon, I appreciate the stats you shared. Is there any way to kind of parse out what you think year 1 cash EPS accretion would look like? And then what the expected closure timing might be for that?

    接著追問一下。關於 Paragon,我很感謝你分享的數據。能否進一步拆解一下,你們認為第一年現金 EPS 的增益大概會是什麼樣子?另外,預期的交割時間點會是何時?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Great questions, Matt. We think the closure -- it's dependent on regulatory approval, but nothing atypical. But we think -- we'll get the approvals and close sometime in the first quarter. In terms of year 1, we'll have a very modest cash EPS accretion. It's going to be impacted by purchase accounting, integration costs, realignment cost to financing costs. We'll pay with this with a mix of cash and debt. And -- but we'll have very strong accretion in year 2. And we're excited about getting the business under our wing, improving the business and delivering. We're very excited.

    很好的問題,Matt。交割時間取決於監管核准,但沒有任何不尋常之處。我們認為——我們會取得核准並在第一季的某個時間完成交割。至於第一年,我們的現金 EPS 增益會非常小。它會受到購買會計、整合成本、重整成本以及融資成本的影響。我們將以現金與負債的組合來支付。第二年則會有非常強勁的增益。我們很期待把這項業務納入旗下、改善業務並交付成果。我們非常興奮。

  • Matt J. Summerville - MD & Senior Research Analyst

    Matt J. Summerville - MD & Senior Research Analyst

  • Just real quick, Dave. So you're not planning to non-GAAP those items out, you're just going to run them through the P&L then?

    很快確認一下,Dave。所以你們不打算把那些項目以非 GAAP 的方式剔除,而是會直接讓它們反映在損益表(P&L)裡嗎?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • We'll make that decision at the time. Historically, we have not broke them out, but with the amount of acquisition activity that we have. It may make sense to do that. We haven't made a decision yet.

    我們會在那個時點再做決定。過去我們通常不會把它們單獨拆出來,但考量到我們目前的併購活動規模,這麼做可能有其合理性。我們還沒有做出決定。

  • Operator

    Operator

  • Our next question comes from Allison Poliniak with Wells Fargo.

    下一個問題來自 Wells Fargo 的 Allison Poliniak。

  • Allison Ann Marie Poliniak-Cusic - Director & Senior Equity Analyst

    Allison Ann Marie Poliniak-Cusic - Director & Senior Equity Analyst

  • Just want to go back to your comments on automation. If I recall, that's typically a canary in the coal mine. But it seems from your comments what I'm reading through, I just want to clarify that it just seems to be more industry destocking for you in that market? Or was it something that -- I want to make sure I understand.

    我想回到你對自動化的評論。如果我沒記錯,自動化通常是景氣的「煤礦裡的金絲雀」。但從你的說法來看,我想確認一下:對你們而言,這看起來更像是該市場的產業去庫存?還是有其他因素——我想確保我理解正確。

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Yes. We think it's destocking. We think it's destocking. And the destocking last through the year-end. And -- but post destocking, we remain constructive. We are -- that business automation sells to a lot of markets and the health care part of that market is not doing well right now and some of the other exposures, but we think it's clearly destocking.

    是的。我們認為是去庫存。我們認為是去庫存,而且去庫存會持續到年底。不過在去庫存之後,我們仍保持正向看法。我們——自動化業務面向很多市場,其中醫療保健相關的那一部分目前表現不佳,還有一些其他曝險,但我們認為這很明顯是去庫存。

  • Allison Ann Marie Poliniak-Cusic - Director & Senior Equity Analyst

    Allison Ann Marie Poliniak-Cusic - Director & Senior Equity Analyst

  • Got it. And then on growth investments, keeping to the $100 million. How should we be thinking about into '24? Is it something that you think there could be a raise there? And then just even with Paragon, what's that R&D? I think you talked about the design piece of it being very -- a big part of that. How does design in R&D? Is it higher than the typical AMETEK? How should we be thinking about?

    了解。接著談成長投資,維持在 1 億美元。對於 2024 年我們應該怎麼看?你覺得有可能提高嗎?另外就 Paragon 而言,他們的研發(R&D)如何?我記得你提到設計是其中很——很重要的一部分。設計在研發中的占比如何?是否高於 AMETEK 的典型水準?我們應該怎麼理解?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • I think you should think about Paragon is matching the AMETEK profile.

    我認為你應該把 Paragon 視為符合 AMETEK 的典型輪廓。

  • Allison Ann Marie Poliniak-Cusic - Director & Senior Equity Analyst

    Allison Ann Marie Poliniak-Cusic - Director & Senior Equity Analyst

  • Got it. And then organic investments as we kind of look to '24 is?

    了解。那麼我們展望 2024 年的有機投資是?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Yes, I mean we're going to sit down with each of our teams, discuss 2024 over the next 6 weeks. We're going to review each of the individual businesses. We do deep dives, as you know, into what they are seeing in their niches, their market dynamics, growth opportunities, cost reduction opportunities, and we want to go through that -- these meetings before there's any commentary in 2024. We'll tell you in early February. But -- so in terms of talking about next year, we'll have the typical things like we expect price to offset inflation and CapEx will be about 2% of sales and things like that. But we're going to defer from talking about the overall plan until we get to meet with our teams and understand at a detailed level.

    是的,我們會在接下來 6 週內與各個團隊坐下來,討論 2024 年。我們會檢視每一個事業單位。你也知道,我們會做深入檢討(deep dives),了解他們在各自利基市場看到的情況、市場動態、成長機會、降本機會等;在對 2024 年做任何評論之前,我們希望先完成這些會議。我們會在 2 月初告訴你們。不過——就明年而言,會有一些典型項目,例如我們預期價格可抵銷通膨、資本支出(CapEx)約為銷售額的 2% 等。但在與團隊會面並在細節層級充分理解之前,我們會暫緩談整體計畫。

  • Operator

    Operator

  • Our next question comes from Jeffrey Sprague with Vertical Research Partners.

    下一個問題來自 Vertical Research Partners 的 Jeffrey Sprague。

  • Jeffrey Todd Sprague - Founder & Managing Partner

    Jeffrey Todd Sprague - Founder & Managing Partner

  • Just to come back to Paragon, maybe one more time. Maybe somebody else will come at it again. I just kind of want to understand the -- maybe the profit improvement plan going forward. Because it looks like rough math right, margins, EBITDA margin is 25% or so. You're doing 800 to 1,000 bps better now than that in EIG.

    再回到 Paragon,可能再問一次,也許其他人也會再問。我想了解一下——未來的獲利改善計畫。因為粗略算一下,利潤率、EBITDA 利潤率大約是 25% 左右。而你們在 EIG 現在的表現比那個水準高出大概 800 到 1,000 個基點。

  • When you talk about kind of the aspirations for the business and the cost cutting and other opportunities, is that the sort of zip code and margin improvement we should be thinking about here? And if so, over kind of how long a period of time?

    當你談到對業務的各種目標、成本削減以及其他機會時,這是否就是我們在這裡應該思考的那個「區間」(zip code)以及利潤率改善幅度?如果是的話,大概會在多長的時間範圍內實現?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Yes. That is the zip code and it's over time. And we're going to build a plan with the management team and show them all the resources that AMETEK has and some of our business processes. But what you're talking about is in the zip code of what we have planned.

    是的。就是那個區間,而且會隨時間逐步實現。我們會和管理團隊一起制定計畫,向他們展示 AMETEK 擁有的所有資源以及我們的一些業務流程。不過你所說的,確實就在我們規劃的那個區間內。

  • Jeffrey Todd Sprague - Founder & Managing Partner

    Jeffrey Todd Sprague - Founder & Managing Partner

  • And just to elaborate a little bit more on how this fits. Is there a kind of a commercial or operational synergy with other parts of the business? Or should we just think of this as an interesting, healthy kind of stand-alone business that drops into the portfolio?

    再稍微延伸一下,談談這如何契合:它是否與公司其他業務部分存在某種商業或營運上的協同效應?還是我們應該把它視為一個有趣、健康、可獨立運作、納入投資組合的業務?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • We have an existing business. And our EMG business, it's about a $200 million business. It's -- or called our engineered medical components. So we're familiar with these segments. There's completely different end markets, but think about that as additive to that existing position, but in a greater scale.

    我們本來就有既有業務。我們的 EMG 業務大約是 2 億美元規模——也就是我們所稱的工程醫療元件(engineered medical components)。所以我們對這些細分領域很熟悉。終端市場完全不同,但可以把它視為在既有布局上做加法,只是規模更大。

  • Jeffrey Todd Sprague - Founder & Managing Partner

    Jeffrey Todd Sprague - Founder & Managing Partner

  • And then maybe just one last one from me. The med tech world has been a little rocky here the last couple of years, procedures post-COVID, everything. You characterized it as a double-digit secular grower. But are they kind of sitting in a little bit of a trough here, impacted by those sorts of forces? Or maybe just kind of the...

    然後也許我最後一個問題。過去幾年醫療科技領域有點顛簸,像是 COVID 後的手術量、各種因素等等。你把它描述為雙位數的長期結構性成長者。但他們是否正處於一個小低谷,受到這類力量影響?或者也許只是……

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • No, not really. They're growing nicely. I mean you have the market growth that they're benefiting from, and they happen to be in the fastest areas. They've deployed their resources well and they're benefiting from the faster -- fastest growth areas.

    不,並沒有。他們成長得很好。我的意思是,他們受惠於市場成長,而且剛好位於成長最快的領域。他們資源部署得很好,並且正在受惠於更快——最快的成長領域。

  • They're winning new business on new programs, it's pretty substantial. And we did surveys on these businesses, and this is a really good business in terms of their capability and how they take care of their customers, and they're definitely winning share. So it's going to be a low double-digit grower for the next few years, and a lot of that's programmed in. Now that's the way we're looking at. There's going to be ups and downs as we go throughout the years, but this is a solid business with really good growth prospects.

    他們在新專案上贏得新業務,規模相當可觀。我們也對這些業務做了調查,從能力以及如何照顧客戶的角度來看,這是一門非常好的生意,而且他們確實正在提升市占。因此未來幾年將是低雙位數成長者,其中很大一部分已經被「寫進」專案規劃裡。這是我們目前的看法。當然,隨著年份推進會有起伏,但這是一個穩健的業務,成長前景非常好。

  • Operator

    Operator

  • Our next question comes from Scott Graham with Seaport Research Partners.

    下一個問題來自 Seaport Research Partners 的 Scott Graham。

  • Scott Graham - Senior Analyst

    Scott Graham - Senior Analyst

  • Nice quarter. So just a couple of items, Bill. What was the working capital percent last year?

    本季表現不錯。所以有幾個問題,Bill。去年營運資金占比是多少?

  • William Joseph Burke - Executive VP & CFO

    William Joseph Burke - Executive VP & CFO

  • Give me one second on that.

    給我一秒鐘。

  • Scott Graham - Senior Analyst

    Scott Graham - Senior Analyst

  • Sure. Sure. I'll just -- I'll ask another one.

    好的,好的。我先——我再問一個。

  • William Joseph Burke - Executive VP & CFO

    William Joseph Burke - Executive VP & CFO

  • I got it. It was 18 4.

    我找到了,是 18.4。

  • Scott Graham - Senior Analyst

    Scott Graham - Senior Analyst

  • 18 4. Okay. And then the $1.5 billion of availability, just maybe walk us through there. That is net of Paragon, I assume? And is that like an assumption at about 2.5x leverage?

    18.4。好的。然後關於 15 億美元的可用額度,能否帶我們梳理一下?我假設這是扣除 Paragon 之後的數字?而且這是否相當於大約 2.5 倍槓桿的假設?

  • William Joseph Burke - Executive VP & CFO

    William Joseph Burke - Executive VP & CFO

  • No, that's the amount of cash and availability under our revolver post-Paragon. The leverage post-Paragon would only be about 1.5x EBITDA at the gross level. So substantial financial flexibility as well as we're still well underlevered, I would say. And as Dave has talked about, lots of other opportunities available to us as we look to continue the acquisition strategy. So again, it's always finding the right businesses for the AMETEK portfolio is not capital constrained.

    不是,那是完成 Paragon 交易後,我們的現金加上循環信貸(revolver)項下的可用額度。完成 Paragon 後的槓桿,在總額層面大約只有 1.5 倍 EBITDA。所以我們有相當大的財務彈性,而且我會說我們仍然是槓桿偏低。正如 Dave 談到的,當我們持續推進併購策略時,還有很多其他機會可供把握。再說一次,關鍵永遠是找到適合 AMETEK 投資組合的正確業務,而不是受資金限制。

  • Scott Graham - Senior Analyst

    Scott Graham - Senior Analyst

  • Right. Right. Yes, that's how you do that as well.

    對,對。是的,你們也是這樣做的。

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Other way to make that, as Bill said, post-Paragon, we have 1.5 leverage. We wanted to take at up to 2.5 leverage, which is we've been there before, and that's not a high number for all. We can spend $2.6 billion on acquisitions, above and beyond Paragon. So we're in the M&A game, and our pipeline looks really good. And we have the balance sheet to be able to execute on it and the capability to integrate these businesses.

    換個方式說,正如 Bill 所說,完成 Paragon 後我們的槓桿是 1.5 倍。我們希望把槓桿提高到最多 2.5 倍——我們以前也到過這個水準,對所有人來說這都不算高。我們在 Paragon 之外,還可以再投入 26 億美元用於併購。所以我們會持續參與併購市場,而且我們的案源管線看起來非常好。我們也有資產負債表來執行,並具備整合這些業務的能力。

  • Scott Graham - Senior Analyst

    Scott Graham - Senior Analyst

  • When you are looking at deals these days in this interest rate environment, you're obviously funding them off of a lot of balance sheet liquidity and admittedly, maybe now higher rates off of the revolver. But are you impute an interest rate that is kind of more market-oriented when you make these decisions?

    在目前這種利率環境下看交易時,你們顯然主要用資產負債表的流動性來資助,並且坦白說,循環信貸的利率現在可能更高。但在做這些決策時,你們是否會假設一個更貼近市場的利率來計算?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Yes. Our models use current borrowing rates as part of that decision-making process.

    是的。我們的模型會把當前借款利率納入決策流程的一部分。

  • Scott Graham - Senior Analyst

    Scott Graham - Senior Analyst

  • Got it. Last question is the typical one, Dave, would you mind kind of maybe unbundling on the four divisions?

    了解。最後一個問題是常見的那個,Dave,你介意把四個事業部拆開說明一下嗎?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Sure, Scott. I'll walk around the business. I'll start with our process business. And -- overall, sales for process were up mid-single digits at low single-digit organic sales and the contribution from the acquisition of Navitar. And demand across our process markets remains solid. Our products and technologies are well aligned with important secular growth trends like the energy transition and health care. Growth in the quarter was strongest across these end markets. While our high-end optics business in Zygo continues to perform very well, with strong demand for our custom optical solutions. And for the full year, we continue to expect mid-single-digit organic sales growth for our Process businesses.

    當然,Scott。我會逐一說明各業務。我先從我們的流程(Process)業務開始。整體而言,流程業務銷售額年增中個位數,其中有機銷售額年增低個位數,並包含收購 Navitar 的貢獻。流程市場的需求仍然穩健。我們的產品與技術與重要的長期結構性成長趨勢高度契合,例如能源轉型與醫療保健。本季成長在這些終端市場最為強勁。同時,我們在 Zygo 的高階光學業務持續表現非常好,對客製化光學解決方案的需求強勁。就全年而言,我們仍預期流程業務的有機銷售額將呈現中個位數成長。

  • Going to Aerospace & Defense Next. Aerospace & Defense continues to perform well. Organic sales were up low double digits in the quarter. Growth remains strong and broad-based across our A&D subsegments. Our growth in the quarter was strongest in our defense businesses, while commercial OEM and aftermarket businesses also grew at healthy levels. Given this strong performance, we now expect sales for Aerospace & Defense to increase mid-teens on a percentage basis for the full year.

    接著是航太與國防(Aerospace & Defense)。航太與國防持續表現良好。本季有機銷售額年增低雙位數。成長在我們 A&D 各子領域仍然強勁且具廣泛性。本季成長最強的是國防業務,而商用 OEM 與售後市場業務也以健康水準成長。鑑於這樣的強勁表現,我們現在預期航太與國防全年銷售額將以百分比計成長中十位數(mid-teens)。

  • In Power & Industrial, those businesses delivered solid results in the third quarter, with overall sales up mid-teens. This growth was driven by a low single-digit organic sales growth and the contribution from the acquisition of RTDS Technologies. We saw the strongest growth in the quarter across our renewable energy and power simulation businesses, including RTDS. Our power businesses are well positioned to benefit from long-term investments required to modernize the electric power grid and build-out of the renewable energy infrastructure globally. And for all of 2023, we continue to expect mid-single-digit organic sales growth for our Power business.

    在電力與工業(Power & Industrial)方面,這些業務在第三季交出穩健成果,整體銷售額年增中十位數(mid-teens)。這項成長來自有機銷售額年增低個位數,以及收購 RTDS Technologies 的貢獻。本季成長最強的是我們的再生能源與電力模擬業務(包含 RTDS)。我們的電力業務具備良好定位,可受惠於長期投資需求:包括電網現代化,以及全球再生能源基礎設施的建置。對於 2023 全年,我們仍預期電力業務的有機銷售額將呈現中個位數成長。

  • And finally, our Automation & Engineered Solutions business. Overall sales for AE&S, were down mid-single digits in the quarter, with contributions from the acquisition of Bison Engineering, being more than offset by a low double-digit decrease in organic sales. As we expected, the impact from normalization of inventory levels, which we talked about earlier, across our OEM customer base, combined with the challenging prior year comparisons, created a short-term headwind for our OEM exposed businesses.

    最後是我們的自動化與工程解決方案(Automation & Engineered Solutions)業務。AE&S 本季整體銷售額年減中個位數;收購 Bison Engineering 的貢獻,被有機銷售額低雙位數下滑所抵銷。如我們所預期,我們先前提到的 OEM 客戶庫存水位正常化影響,加上去年同期比較基期具挑戰性,對我們 OEM 曝險較高的業務造成短期逆風。

  • We believe underlying demand is solid. As we talked about earlier, and across our diverse Automation & Engineered Solutions markets, we remain constructive. But we do expect, as we said before, the inventory normalization is going to recur throughout the OEM customer base will continue through the end of the year. And now for the full year, we expect organic sales for our Automation & Engineered Solutions businesses to be down mid-single digits versus the prior year. So that's all for the subsegment commentary here, Scott.

    我們認為基本需求仍然穩健。如同先前所說,在多元的自動化與工程解決方案市場中,我們仍保持建設性看法。但我們也預期——正如之前所說——OEM 客戶群的庫存正常化將會反覆出現,並持續到年底。現在就全年而言,我們預期自動化與工程解決方案業務的有機銷售額將較去年下滑中個位數。以上就是這裡對子領域的說明,Scott。

  • Operator

    Operator

  • Our next question comes from Nigel Coe with Wolfe Research.

    下一個問題來自 Wolfe Research 的 Nigel Coe。

  • Nigel Edward Coe - MD & Senior Research Analyst

    Nigel Edward Coe - MD & Senior Research Analyst

  • Congrats on the deal, deals even. Okay, good, I couldn't hear you. Okay so maybe you could do the same process geographically, talk about what you're seeing by geography. I'd be curious about Europe and China. And also, you gave some perspective on business performance. Maybe you could talk about -- maybe just for a final point on 4Q. Maybe talk about core growth and acquisition and contribution for 4Q.

    恭喜這筆交易——甚至是多筆交易。好,好的,我剛剛聽不太清楚你。好,那也許你可以用同樣的方式,按地理區域來談談你們看到的情況。我特別想了解歐洲和中國。另外,你也提供了一些業務表現的觀點。也許你可以談談——作為最後一點,關於第四季(4Q)。也許談談 4Q 的核心成長、併購以及併購貢獻。

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Okay. Q4 and geography. Okay. I'll go across the geographies. We had continued solid growth in the U.S., with the international slowing a bit. So I'll unpack that a bit. The U.S. was up mid-single digits, with notable strength in our process business. Europe was down low single digits, notable strength in Process and our Aerospace business, but weakness in Automation.

    好的。第四季和地理區域。好,我會按地理區域逐一說明。我們在美國持續穩健成長,而國際市場則稍微放緩。我來拆解一下。美國年增中個位數,流程業務表現尤為突出。歐洲年減低個位數,流程業務與航太業務有明顯強勢,但自動化業務偏弱。

  • You mentioned China. Our China exposure was down 3%. Strong growth in Process, weakness in Automation. And overall, Asia was down about 10%. So China did better than overall Asia, kind of about 9% of sales. So again, up in the U.S., slowing in international markets. And the second question you asked was on Q4 and the guide for Q4. And our sales will be up mid-single digits. We'll grow in revenue. There are two factors impacting the earnings in Q4 and one of them is a higher tax rate. And the second one is there's some acquisition, integration costs and they're related to the deals we completed. But we're very confident in our guide for Q4.

    你提到中國。我們在中國的曝險下滑 3%。流程業務強勁,自動化業務偏弱。整體亞洲約下滑 10%。因此中國表現優於整體亞洲;中國約占銷售額的 9%。所以再說一次,美國上升,國際市場放緩。你問的第二個問題是第四季以及第四季指引。我們的銷售額將年增中個位數,營收會成長。第四季有兩個因素影響獲利,其中之一是較高的稅率;第二個是一些併購整合成本,與我們完成的交易相關。但我們對第四季指引非常有信心。

  • Nigel Edward Coe - MD & Senior Research Analyst

    Nigel Edward Coe - MD & Senior Research Analyst

  • I'm sorry, David, what is the core growth for 4Q?

    抱歉,David,第四季的核心成長是多少?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Core growth for Q4 was low to mid-single digits.

    第四季的核心成長為低到中個位數百分比。

  • Nigel Edward Coe - MD & Senior Research Analyst

    Nigel Edward Coe - MD & Senior Research Analyst

  • Okay. So that's obviously acceleration from 3Q. What's driving that acceleration?

    好的。所以這顯然是相較第三季的加速。是什麼在推動這個加速?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • I think we're seeing some good demand on the EIG side from the typical year-end selling -- year-end sales that we typically get of capital spending, plus the EIG business is performing well. So our Aerospace and our Process businesses are performing well, and that's what driving the organic sales in Q4 to be higher than the organic sales in Q3.

    我認為我們在 EIG 端看到一些不錯的需求,來自典型的年底銷售——也就是我們通常在年底會出現的資本支出相關銷售,加上 EIG 業務表現良好。因此,我們的航太以及流程業務表現都很好,這就是推動第四季有機銷售高於第三季有機銷售的原因。

  • Nigel Edward Coe - MD & Senior Research Analyst

    Nigel Edward Coe - MD & Senior Research Analyst

  • Got it. That's helpful. Maybe just one more for me. So obviously, Paragon, big deal. You've posed another smaller deal. You sound really bullish on the outlook as well. So it seems like the cut line is still pretty fertile. I mean are we seeing here a change in behavior from sellers that we see more willing sellers? Are we seeing any change in sort of (inaudible) multiples here? Any color on the market would be helpful.

    了解。這很有幫助。也許我再問一個。很明顯,Paragon 是一筆大交易。你們也提出了另一筆較小的交易。你們聽起來對前景也非常樂觀。所以看起來併購標的仍然相當充沛。我是說,我們是否看到賣方行為有所改變,變得更願意出售?我們是否看到(聽不清)倍數方面有任何變化?如果能提供一些市場面的資訊會很有幫助。

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Yes, I think it's a little choppy in the market and people are reevaluating. And the interest rates are higher. So financing that debt on a continuing organization may be a challenge. And as I said in the beginning of the year, our pipeline is strong. I would categorize our pipeline right now is very strong. We have a lot of attractive candidates we're looking at. And I'm just bullish on being able to differentiate AMETEK's performance over the next 12 to 24 months with our OpEx and our M&A.

    是的,我認為市場有點顛簸,大家正在重新評估。而且利率更高,因此對持續經營的組織而言,為那筆債務進行融資可能會是一項挑戰。正如我在年初所說,我們的案源管線很強。我會把我們目前的管線形容為非常強。我們正在看很多具吸引力的候選標的。而且我對於在未來 12 到 24 個月,透過我們的營運卓越(OpEx)與併購(M&A)來凸顯 AMETEK 的表現差異化,抱持樂觀。

  • Operator

    Operator

  • Our next question comes from Christopher Glynn with Oppenheimer.

    下一個問題來自 Oppenheimer 的 Christopher Glynn。

  • Christopher D. Glynn - MD & Senior Analyst

    Christopher D. Glynn - MD & Senior Analyst

  • I want to keep it going on Paragon a little bit. I think you listed as -- for medical components and instruments. I'm wondering if it is the OEM and some of the instrument spaces? And also a little bit on ownership history and the deal process, competitiveness and such.

    我想再多談一點 Paragon。我記得你們把它列為——醫療零組件與儀器。我想了解它是否涵蓋 OEM 以及部分儀器領域?另外也想請教一下其股權/所有權歷史,以及交易流程、競爭程度等等。

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Yes. When you think about Paragon, they're largely selling to an OEM customer base, but they do sell some of their surgical instruments directly to the end customer, but it's largely an OEM customer base. We purchased the business from American Securities. And from our view, they did an excellent job running the business and got a fantastic management team in place, have a good growth strategy. And they're -- what they did is really position kind of a pure med tech play, by positioning this with some other parts of their portfolio. So we're pretty excited about what we're buying.

    是的。談到 Paragon,他們主要是銷售給 OEM 客戶群,但也有一部分手術器械是直接銷售給終端客戶,不過整體仍以 OEM 客戶群為主。我們是向 American Securities 收購這項業務。從我們的角度來看,他們把這家公司經營得非常出色,並建立了一支很棒的管理團隊,也有良好的成長策略。而且——他們所做的是,透過把它與其投資組合中的其他部分進行定位,將其打造為一個相對純粹的醫療科技(med tech)標的。因此我們對於所收購的內容感到相當興奮。

  • Operator

    Operator

  • Our next question comes from Peter Costa with Mizuho.

    下一個問題來自 Mizuho 的 Peter Costa。

  • Peter James Costa - Associate

    Peter James Costa - Associate

  • This is Peter as on for Brett Linzey. So just coming back to orders. Could you provide some context during the monthly order cadence through the quarter and then moving into October? Have you been seeing anything concerning or anything tracking better than your internal expectations?

    我是 Peter,代替 Brett Linzey 提問。回到訂單方面,能否提供一些背景,說明本季各月份的接單節奏,以及進入 10 月後的情況?你們是否看到任何令人擔憂的跡象,或是有任何表現優於你們內部預期的地方?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • No. I think the quarterly evolution of orders is about what we see. We mentioned our book-to-bill and things like that. And we started out in Q4, in line with what we need to deliver those results. So we had talked -- in our last few earnings calls, we highlighted a couple of dynamics that would impact orders, and our orders have been very strong for an extended period of time. In fact, we averaged 18% organic growth in 2021 and 2022, and we had 12 consecutive quarters up to this quarter with positive book-to-bill. So as a result, we have a near record backlog, as we said, the dynamics are playing out as we anticipated.

    沒有。我認為訂單在季度內的演變大致符合我們一貫所見。我們也提到過出貨比(book-to-bill)等指標。而我們在第四季一開始的表現,與我們達成那些結果所需的水準一致。我們在最近幾次財報電話會議中也強調了幾個會影響訂單的動態,而我們的訂單在相當長一段時間內都非常強勁。事實上,我們在 2021 與 2022 年的有機成長平均為 18%,而且截至本季之前,我們連續 12 個季度的出貨比都為正。因此,如我們所說,我們的在手訂單(backlog)接近歷史高點,這些動態正如我們預期般發展。

  • Operator

    Operator

  • Our next question comes from Andrew Obin with Bank of America.

    下一個問題來自美國銀行(Bank of America)的 Andrew Obin。

  • David Emerson Ridley-Lane - VP

    David Emerson Ridley-Lane - VP

  • This is David Ridley-Lane on for Andrew Obin. Wondering if you've seen any impact from the higher interest rates on end market demand? And in particular, some of the other publicly traded test and measurement companies have mentioned project delays, particularly in China. Have you seen anything along those lines?

    我是 David Ridley-Lane,代替 Andrew Obin 提問。想請教你們是否看到較高利率對終端市場需求造成任何影響?特別是,其他一些上市的測試與量測公司提到專案延遲,尤其是在中國。你們是否也看到類似情況?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Yes. As I mentioned, we were down about 3% organically in China. So there was some delays, but it wasn't substantial. In terms of increasing interest rates, that's one of the uncertainties that we're clearly looking at. And it's a very dynamic environment right now. And there are factors for sure, but we're not seeing an impact on projects proceeding or anything like that from the interest rates at this point.

    是的,如我提到的,我們在中國的有機成長約下滑 3%。所以確實有一些延遲,但並不嚴重。就利率上升而言,這是我們明確在關注的不確定因素之一。目前環境非常動態,確實存在一些因素,但截至目前,我們尚未看到利率對專案推進或類似事項造成影響。

  • David Emerson Ridley-Lane - VP

    David Emerson Ridley-Lane - VP

  • Got it. And are you supply chain constrained at this point in your aerospace and defense businesses? Is that a sort of a limiter on growth accelerating and even greater over time?

    了解。那你們在航太與國防業務方面,目前是否受到供應鏈限制?這是否會限制成長加速、以及未來更大幅度的成長?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • We are not supply chain limited in aerospace at this time. Now the industry is dealing with some supply chain difficulties, but we're not limited.

    目前我們在航太方面不受供應鏈限制。當然,整個產業正面臨一些供應鏈困難,但我們並未受限。

  • Operator

    Operator

  • Our next question comes from Michael Anastasiou with TD Cowen.

    下一個問題來自 TD Cowen 的 Michael Anastasiou。

  • Michael Anastasiou - Associate

    Michael Anastasiou - Associate

  • Back to Paragon, currently, medical-related revenues are about, give or take, 10% of sales. And after this acquisition, it takes you to about 20%. So was just expecting -- just curious if you're expecting to make like a deeper push into medical moving forward? And then what is sort of like the best way to think about balancing M&A dollars for these different end markets as well? Any color would be helpful.

    回到 Paragon。目前醫療相關營收大約占銷售額的 10% 左右。完成這次收購後,將提升到約 20%。所以我原本預期——也想請教你們是否預期未來會更深入推進醫療領域?另外,對於不同終端市場,應該如何看待併購資金(M&A dollars)的配置平衡?任何補充說明都會很有幫助。

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Yes, there's a balance in AMETEK's end markets, and we really like that balance. That's why we're able to navigate some of the challenges that we're going through right now. So it's -- we plan on keeping that balance. But if there are other attractive areas in the medical space, we'll certainly look at them. But it's -- we like the balance in the portfolio.

    是的,AMETEK 的終端市場之間是有平衡的,而我們非常喜歡這種平衡。這也是為什麼我們能夠因應目前正在面對的一些挑戰。所以——我們計畫維持這種平衡。但如果醫療領域還有其他具吸引力的方向,我們當然也會評估。不過——我們喜歡投資組合中的這種平衡。

  • And what was your other question, Michael? M&A dollars. I mean we have a distributed operating model. In all of our businesses, we have management teams there that are doing strategy work around their businesses and trying to make their businesses better, and they're bringing forward acquisition candidates. So we don't have a predefined number of -- predefined amount of capital that we're going to apply to certain markets. We're going to be looking for the deal, the deal quality, the quality of the businesses and if we have the management teams to integrate them. So we have a different viewpoint. We don't look at it from the top down in terms of dollars allocated per market.

    Michael,你的另一個問題是什麼?併購資金。我們採取分散式的營運模式。在我們所有業務中,都有管理團隊在針對各自業務做策略工作、努力讓業務變得更好,並提出收購候選標的。因此,我們沒有預先設定——沒有預先設定要把多少資本投入到特定市場。我們會看交易本身、交易品質、企業品質,以及我們是否有管理團隊能夠整合它們。所以我們的觀點不同;我們不會以自上而下的方式,按市場分配資金額度來看待。

  • Michael Anastasiou - Associate

    Michael Anastasiou - Associate

  • Got you. That's helpful. And just kind of diving back into it. So potentially, depending on availability of assets and as such, do you expect total revenues to the medical end market increasing over time? And how do you expect that?

    了解。這很有幫助。再深入一點問,視資產供給等情況而定,你們是否預期醫療終端市場的總營收占比會隨時間提高?你們預期會如何發展?

  • David A. Zapico - Chairman of the Board & CEO

    David A. Zapico - Chairman of the Board & CEO

  • Yes, it's 20% now. It could go 25%, 30%, that wouldn't bother us. But we plan on having a diversified revenue base.

    是的,現在是 20%。提高到 25%、30% 也不會困擾我們。但我們計畫維持多元化的營收基礎。

  • Operator

    Operator

  • That concludes the question-and-answer session. At this time, I would like to turn it back to Kevin Coleman for closing remarks.

    問答環節到此結束。接下來我想把時間交回 Kevin Coleman 作結語。

  • Kevin C. Coleman - VP of IR & Treasurer

    Kevin C. Coleman - VP of IR & Treasurer

  • Thank you, Abigail, and thanks, everyone, for joining us for our conference call. As a reminder, a replay of today's webcast can be accessed in the Investors section of ametek.com. Have a great day.

    謝謝你,Abigail,也謝謝各位參加我們的電話會議。提醒各位,今天網路直播的重播可在 ametek.com 的投資人(Investors)專區收看。祝各位有美好的一天。

  • Operator

    Operator

  • Thank you for your participation in today's conference. This does conclude the program. You may now disconnect.

    感謝各位參與今天的會議。至此本次活動結束。您現在可以斷線。